← Back to Screener
Kalaris Therapeutics, Inc. Common Stock (KLRS)
Price$4.44
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-36.77%
Price vs S&P 500 (4W)-12.59%
VGM Score35.30
Market Capitalization$96.91M
All Metrics
Book Value / Share (Quarterly)$2.98
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.86
Price vs S&P 500 (YTD)-55.55%
EPS (TTM)$-2.21
10-Day Avg Trading Volume0.09M
EPS Excl Extra (TTM)$-2.21
EPS (Annual)$-11.78
ROI (Annual)-52.07%
Cash / Share (Quarterly)$4.23
ROA (Last FY)-49.77%
EBITD / Share (TTM)$-2.36
ROE (5Y Avg)-70.78%
Cash Flow / Share (Annual)$-1.68
P/B Ratio1.41x
P/B Ratio (Quarterly)1.93x
Net Income / Employee (Annual)$-2,950,000
ROA (TTM)-43.49%
EPS Incl Extra (Annual)$-11.78
Current Ratio (Annual)12.23x
Quick Ratio (Quarterly)12.08x
3-Month Avg Trading Volume0.08M
52-Week Price Return42.77%
Revenue / Employee (TTM)$0
P/S Ratio (Annual)570.08x
Asset Turnover (Annual)0.00x
52-Week High$11.88
EPS Excl Extra (Annual)$-11.78
CapEx CAGR (5Y)-3.58%
26-Week Price Return-28.85%
Quick Ratio (Annual)12.15x
13-Week Price Return-54.11%
Total Debt / Equity (Annual)0.41x
Current Ratio (Quarterly)12.19x
Enterprise Value$94.56M
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-14023.53%
Cash / Share (Annual)$5.15
3-Month Return Std Dev73.67%
Net Income / Employee (TTM)$-2,204,900
ROE (Last FY)-52.07%
EPS Basic Excl Extra (Annual)$-11.78
Total Debt / Equity (Quarterly)0.47x
EPS Incl Extra (TTM)$-2.21
ROI (TTM)-47.59%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)18.40%
Year-to-Date Return-47.39%
5-Day Price Return-9.39%
EPS Normalized (Annual)$-11.78
ROA (5Y Avg)-57.85%
Net Profit Margin (Annual)-14023.53%
Month-to-Date Return-15.75%
EBITD / Share (Annual)$-12.97
Operating Margin (Annual)-15705.88%
LT Debt / Equity (Annual)0.41x
ROI (5Y Avg)-70.78%
LT Debt / Equity (Quarterly)0.47x
EPS Basic Excl Extra (TTM)$-2.21
P/B Ratio (Annual)1.79x
Book Value / Share (Annual)$3.44
Price vs S&P 500 (13W)-62.36%
Beta0.23x
P/FCF (Annual)49.96x
Revenue / Share (TTM)$0.00
ROE (TTM)-72.78%
52-Week Low$2.14
mGradeD
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-0.46est. -0.53
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.25
4.25
4.23
4.29
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
KLRSKalaris Therapeutics, Inc. Common Stock | — | — | D | $4.44 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
Kalaris Therapeutics is a clinical-stage biopharmaceutical company developing TH103, a next-generation anti-VEGF therapy for exudative and neovascular retinal diseases. The humanized fusion protein is designed to provide longer-lasting and enhanced anti-VEGF activity compared to existing treatments. The company targets prevalent retinal disease markets with significant unmet patient needs.